[1] Sanghani A, Andriesei P, Kafetzis KN, Tagalakis AD, Yu-Wai-Man C. Advances in exosome therapies in ophthalmology-From bench to clinical trial. Acta Ophthalmol. 2022 May;100(3):243-252. doi: 10.1111/aos.14932. Epub 2021 Jun 11. PMID: 34114746.
[2] Harrell CR, Djonov V, Volarevic V. Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Ocular Graft-Versus-Host Disease. Int J Mol Sci. 2022 Oct 31;23(21):13254. doi: 10.3390/ijms232113254. PMID: 36362040; PMCID: PMC9656879.
[3]Harrell CR, Volarevic V, Djonov V, Volarevic A. Therapeutic Potential of Exosomes Derived from Adipose Tissue-Sourced Mesenchymal Stem Cells in the Treatment of Neural金大發娛樂城, and Retinal Diseases. Int J Mol Sci. 2022 Apr 19;23(9):4487. doi: 10.3390/ijms23094487. PMID: 35562878; PMCID: PMC9105552.
[4] Mead B, Amaral J, Tomarev S. Mesenchymal Stem Cell-Derived Small 包皮凝露,Extracellular Vesicles Promote Neuroprotection in Rodent Models of Glaucoma. Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):702-714. doi: 10.1167/iovs.17-22855. PMID: 29392316; PMCID: PMC5795911.
[5皮癬藥膏,] Bai L, Shao H, Wang H, Zhang Z, Su C, Dong L, Yu B, Chen X, Li X, Zhang X. Effects of Mesenchymal Stem Cell-Derived Exosomes on Experimental Autoi妹妹une Uveitis. Sci Rep. 2017 Jun 28;7(1):4323. doi: 10.1038/s41598-017-04559-y. Erratum in: Sci Rep. 2018 Jun 26;8(1):9889. doi: 10.1038/s41598-018-28151-0. PMID: 28659587; PMCID: PMC5489510.